Search
lebrikizumab (Ebglyss)
Indications:
- treatment of atopic dermatitis (FDA-approved Sept 2024)
* FDA denied approval of lebrikizumab for treatment of atopic dermatitis in Oct 2023
Dosage:
- 500 mg (2 250 mg injections) at baseline & week 2
- follow by 250 mg every 2 weeks until week 16 or later when adequate clinical response is achieved
- maintenance: 250 mg every 4 weeks
Adverse effects:
- eye & eyelid inflammation
- injection site reactions
- herpes zoster (shingles)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Reuters. Oct 2, 2023
U.S. FDA declines to approve Eli Lilly's drug to treat eczema
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-eli-lillys-skin-disease-drug-2023-10-02/
- Brunk D
FDA Approves Lebrikizumab for Atopic Dermatitis
Medscape. September 14, 2024
https://www.medscape.com/viewarticle/fda-approves-lebrikizumab-atopic-dermatitis-2024a1000gpu